A clinical trial on the safety of combination therapy with dendritic cell vaccine pulsed with neoantigen peptides and immune check point inhibitor for malignant tumor.

Takimoto Rishu0 个研究点目标入组 3 人开始时间: 2021年7月6日最近更新: 2024年4月1日

适应症

试验速览

The study is terminated due to lack of hope for case enrollment.

•(1)Be diagnosed with malignant tumor by imaging findings or pathological or cytological study.
•(2)Have a successful genetic analysis of tumor sample at Seta Clinic Tokyo or production of neoantigen DCs at Seta Clinic Tokyo.
•(3)Have an Eastern Cooperative Oncology Group performance-status score of 0 or 1.
•(4)Visit outpatient department on schedule.
•(5)Have an adequate function of liver, kidney, and bone marrow when the eligibility is confirmed.
•(6) Provide agreement of the attending doctor to participate in this study.
•(7) Have a backup hospital in the case of emergency.
•(8)Provide written consent to participate this study.

•(1)Be apparent from the clinical manifestation of pulmonary fibrosis or interstitial pneumonia.
•(2)Have a history of a serious drug allergy.
•(3)Have a positive result of HIV antibody.
•(4)Have a serious cardiac disorder.
•(5)Have an active autoimmune disorder.
•(6)Have a concurrent cancer.
•(7)Have an infectious disorder that is difficult to control.
•(8)Be a female who is pregnant, lactating, or with a possibility of pregnancy.
•(9)A patient who is judged as inadequate for enrolment by doctors is excluded

发起方

Takimoto Rishu